Bisphosphonates vs placebo/observation
Bisphosphonates probably leads to lower bone metastases compared with placebo/observation (moderate certainty).
- RR 0.86 [0.75, 0.99]11 studies · 15005 participantsModerate
Bisphosphonates probably leads to lower bone metastases compared with placebo/observation (moderate certainty).
Bisphosphonates showed no clear difference in bone metastases compared with placebo/observation (moderate certainty).
Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (high certainty).
Bisphosphonates leads to lower skeletal‐related event (SRE) compared with placebo/observation (high certainty).
Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
Bisphosphonates leads to lower overall survival compared with placebo/observation (high certainty).
Bisphosphonates leads to lower overall survival postmenopausal women compared with placebo/observation (high certainty).
Bisphosphonates showed no clear difference in overall survival: pre‐ or perimenopausal women compared with placebo/observation (high certainty).
Bisphosphonates showed no clear difference in disease‐free progression compared with placebo/observation (high certainty).
Bisphosphonates leads to lower disease‐free progression: postmenopausal women compared with placebo/observation (high certainty).
Bisphosphonates showed no clear difference in disease‐free progression: pre‐ or perimenopausal women compared with placebo/observation (high certainty).
Bisphosphonates showed no clear difference in fracture incidence compared with placebo/observation (moderate certainty).